DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Miscellaneous/Final Results B.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN publishes annual report and confirms preliminary financials for fiscal year 2015/16 16.01.2017 / 15:00 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- BRAIN publishes annual report and confirms preliminary financials for fiscal year 2015/16 Zwingenberg, January 16, 2017: Just less than one year after the IPO, B.R.A.I.N. Biotechnology Research and Information Network AG ("BRAIN AG"; ISIN DE0005203947 / WKN 520394) today publishes its first annual report as a listed company, confirming the preliminary figures for the fiscal year 2015/16. These had been announced on December 19, 2016, already. Accordingly, during the reporting period from October 1, 2015 to September 30, 2016, the BRAIN-Group slightly increased its total operating performance to EUR 26.1 million from EUR 25.7 million in the previous year. In Q4 2015/16 alone, the total operating performance of the Group increased by 18% compared to Q3 2015/16. The yearly revenues of both Group segments "BioIndustrial" and "BioScience" increased by 8% to EUR 22.8 million. The fiscal year 2015/16 was significantly influenced by the IPO in February 2016 with its related costs and one-off effects as well as by partly difficult market developments. Nonetheless, the company continues to expect the EBIT break-even to be achieved as planned in fiscal year 2017/18. The Management Board is still satisfied with the past financial year: "The successful course of our IPO shows that the bioeconomy is accepted and understood as a future-oriented topic and is also indisputably recognized in capital market circles as a future sector. It is our aim to establish BRAIN long-term and sustainably as a substantial market participant of the bio-based economy", says Jürgen Eck, CEO of BRAIN AG. For many years, BRAIN has been reporting on the company's work in quarterly reports which have won multiple communications and design awards. In addition to the audited group financials and discussions, the BRAIN annual report, entitled "Engineering Biology", also provides exciting insights into the world of biodiversity, BRAIN's own BioArchive, the product pipeline, more detailed information on the strategic partnerships and selected programs of the BRAIN-Group, as well as a summary of the highlights of the financial year. The annual report can now be accessed at www.brain-biotech.de/investor- relations/financial-publications/. Upon request, a printed copy can be sent by post as soon as it is available. About BRAIN BRAIN is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of Bioeconomy. As such, BRAIN identifies previously untapped, efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by help of this "Toolbox of Nature" are successfully applied in the chemistry, the cosmetics and the food industries. Today, BRAIN's business model is based on two pillars - "BioScience" and "BioIndustrial". The first pillar, "BioScience", comprises its - frequently exclusive - collaboration business with industrial partners. The second pillar "BioIndustrial" comprises the development and commercialisation of BRAIN's own products and active product components. Further information is available at www.brain- biotech.de/en Contact: B.R.A.I.N Biotechnology Research And Information Network AG Dr. Martin Langer Executive Vice President Corporate Development Darmstädter Str. 34-36 64673 Zwingenberg, Germany Tel.: +49-6251-9331-16 Fax: +49-6251-9331-11 E-Mail: [email protected] www.brain-biotech.de Disclaimer This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are not guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward- looking statements. --------------------------------------------------------------------------- 16.01.2017 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: B.R.A.I.N. Biotechnology Research And Information Network AG Darmstädter Straße 34-36 64673 Zwingenberg Germany Phone: +49 (0) 62 51 / 9331-0 Fax: +49 (0) 62 51 / 9331-11 E-mail: [email protected] Internet: www.brain-biotech.de ISIN: DE0005203947 WKN: 520394 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 536589 16.01.2017